Elizabeth Stuller
Addiction Psychiatry · Baltimore, MDNPI 1326177718
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Axsome Therapeutics, Inc. accounts for 65.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $14,786 and has fallen 84.7% since, to $2,267 in 2025.
Across 436 payments — averaging $93.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$27K
- Jazz Pharmaceuticals Inc.$6K
- Johnson & Johnson$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$817
- Teva Pharmaceuticals USA, Inc.$608
- plus $3K from 15 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Consulting fees$20,00049%
- Speaking & faculty fees$7,87019%
- Travel & lodging$3,91110%
- Food & beverage$9,00922%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 55 | $26,751 |
| Jazz Pharmaceuticals Inc. | 17 | $6,498 |
| Johnson & Johnson | 62 | $1,836 |
| AbbVie(2 entities) | 71 | $1,415 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $817 |
| Teva Pharmaceuticals USA, Inc. | 20 | $608 |
| Lundbeck LLC | 27 | $516 |
| Otsuka America Pharmaceutical, Inc. | 31 | $444 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $436 |
| Vanda Pharmaceuticals Inc. | 20 | $404 |
| Corium, LLC | 19 | $331 |
| Avanir Pharmaceuticals, Inc. | 21 | $299 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Alkermes, Inc. | 5 | $95 |
| Braeburn Inc. | 1 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| Orexo US, Inc. | 3 | $47 |
| Shire North American Group Inc | 2 | $32 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Indivior Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUNOSI$32,013
- INVEGA SUSTENNA$457
- INVEGA TRINZA$452
- SPRAVATO$383
- UZEDY$244
- VRAYLAR$236
- QUVIVIQ$125
- Fanapt$124
- AUSTEDO$116
- INVEGA$112
How this compares
Too few addiction psychiatry providers in Marylandto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 23 | $21,090 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $1,505 |
| Clozapine | 25 | $828 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $812 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $703 |
| Alprazolam | 20 | $398 |
| Clonazepam | 20 | $244 |
| Lorazepam | 14 | $163 |
| Sertraline Hcl | 13 | $132 |
| Divalproex Sodium | 12 | $119 |
| Zolpidem Tartrate | 18 | $53 |
| Eszopiclone | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $817 | $21,09023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other addiction psychiatry in Baltimore
- Christopher HoltBaltimore$962
- Nicholas ScottoBaltimore$827
- Moira BogrovBaltimore$321
- Joy ChangBaltimore$154
- Allison MalcolmSykesville$561
- Brian LernerHavre de Grace$351
- Bikash SharmaEllicott City$326
- Linda FullerRockville$231
- Mona ThapaEmmitsburg$197
- John CarrSilver Spring$172
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.